GlassScriptPhysician profile
Ashley Nicole Lance
NPI 1629323365
$2,202.32
in general payments reported to CMS, 2019-2025
25 companies · $864 in 2025
The $864 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.56 · 2022: $91.24 · 2023: $558 · 2024: $678 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $781.93 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $387.17 | 2023-2025 | |
| Astellas Pharma US INC | $155.30 | 2023-2025 | Veozah |
| Lilly USA, LLC | $143.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $135.07 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $65.57 | 2024-2025 | Repatha, Otezla, Otezla |
| Eisai INC. | $62.70 | 2024 | |
| Glaxosmithkline, LLC. | $46.05 | 2023-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $44.90 | 2023-2024 | Rexulti |
| Insulet Corporation | $40.93 | 2024-2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.74 | 2025 | Caplyta |
| Lundbeck LLC | $37.29 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $30.56 | 2024 | Gemtesa |
| Scilex Pharmaceuticals INC. | $30.44 | 2023-2024 | Ztlido |
| Phathom Pharmaceuticals, INC. | $27.66 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.45 | 2025 | Injectafer |
| Boston Scientific Corporation | $24.32 | 2025 | Watchman Flx |
| Axsome Therapeutics, INC. | $17.89 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $17.53 | 2025 | Nexletol |
| Protega Pharmaceutials INC | $17.41 | 2024 | Roxybond |
| Ironwood Pharmaceuticals, INC | $15.36 | 2024 | |
| Pfizer INC. | $14.90 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2023 | Xifaxan, Trulance |
| Vertex Pharmaceuticals Incorporated | $14.34 | 2025 | |
| Ardelyx, INC. | $13.53 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.